Description
Melanotan II, a synthetic derivative of α-melanocyte stimulating hormone (α-MSH), originated from research conducted at The University of Arizona and the Arizona Cancer Center. Developed as a shortened, cyclic variant of melanotan-1, Melanotan II was initially investigated for its ability to induce dermal pigmentation sans sunlight exposure. However, its unexpected side effects, including libido enhancement and spontaneous erections, have led to its potential application as a treatment for sexual and erectile dysfunction.
Both Melanotan (MT) and Melanotan II (MT-II) are analogs of α-MSH, a hormone naturally produced in the pituitary gland. Alongside other melanocortins, they regulate various physiological functions such as skin and hair pigmentation, appetite, libido, and sexual arousal. Notably, while these effects are observed in both genders, libido enhancement and sexual function improvements are specific to MT-II.
Clinical studies have demonstrated that both Melanotan and Melanotan II can stimulate pigmentation in the absence of UV exposure, a phenomenon corroborated anecdotally by users reporting tanning in typically unexposed body areas. However, UV exposure significantly accelerates the tanning process. Variations in tanning effects across the skin may occur due to the drug’s half-life, distribution, and the concentration of melanocytes in specific skin regions. Typically, the face, arms, and abdominal region exhibit the most noticeable tanning effects, while areas with high melanocyte concentrations, such as the genitals, respond particularly well to the peptide in conjunction with UV exposure.
- Melanotan II synthesis
- Synthetic α-MSH derivative
- Sexual dysfunction treatment
- Pigmentation enhancement peptide
- UV-induced tanning effects